Mohamed joined the Sussex Drug Discovery Centre (SDDC) in September 2016 after spending one year at Institut de Chimie des Substances Naturelles (ICSN-CNRS, Gif-sur-Yvette, France) as a postdoctoral research fellow (group of Dr. Robert H. Dodd and Dr. Kevin Cariou). During this period, he contributed to the discovery of novel classes of carbapenemases and beta-lactamases inhibitors to combat multidrug-resistant gram negative bacteria.

He obtained a MSc in Organic Chemistry from Université Paris-Sud (Orsay, France) in 2010 and a PhD in Medicinal Chemistry from Université de Franche-Comté (Besançon, France) in 2014. His doctorate project dealt with the preparation and the pharmacological evaluation of novel Ugi and Passerini adducts as multitarget-directed ligands for Alzheimer’s disease therapy.

Currently at the SDDC, Mohamed is involved in the discovery and lead optimisation of novel and selective GABAAR positive allosteric modulators for the treatment of the generalised anxiety disorder.


Research Fellow in Medicinal Chemistry